Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide in Cystic Fibrosis with Abnormal Glucose Tolerance
NCT04731272Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dulaglutide biosimilar 14028 injection in impaired glucose tolerance (IGT), cystic fibrosis-related diabetes (CFRD), sponsored by University of Pennsylvania. Started Jul 2021; status: recruiting.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
impaired glucose tolerance (IGT)cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT04731272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731272.